Abstract
The phenethyl ester analogues of cholecystokinin, OPE and JMV-180, are fully efficacious rat pancreatic secretagoguges which, unlike cholecystokinin (CCK), do not elicit supramaximal inhibition of secretion, and stimulate a sustained rise of cytosolic calcium ([Ca2+]i) above basal levels. We have recently shown that low-level protein kinase C (PKC) activation by preincubation of acini with 1 nM 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or minimally secreting concentrations of PKC-activating receptor agonists (1 pM CCK-8, 0.1 μM carbachol or 10 μM bombesin) cause supramaximal inhibition of OPE-stimulated enzyme secretion. We now show that treatment of acini under these conditions also suppresses the sustained rise of [Ca2+]istimulated by OPE to basal levels in these cells, without changing the initial OPE-stimulated [Ca2+]ipeak. The resultant pattern of calcium signalling is similar to that evoked by supramaximal concentrations of native CCK. This suggests that even low concentrations of PKC-activating agonists have the potential to induce inhibitory effects on Ca2+ mobilization and that this kinase is important in generating the supramaximal inhibition observed in response to CCK.
Original language | English (US) |
---|---|
Pages (from-to) | 450-453 |
Number of pages | 4 |
Journal | Pancreas |
Volume | 9 |
Issue number | 4 |
DOIs | |
State | Published - Jul 1994 |
Keywords
- Camobilization
- Cholecystokinin
- Heterologous agonists
- OPE
- Pancreatic acinar cell
- Protein kinase C
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Endocrinology